文献速递血液净化与透析

西罗莫司涂层球囊治疗功能不良血液透析动静脉内瘘的随机对照研究

Randomized Controlled Study of Sirolimus-Coated Balloons for Dysfunctional Hemodialysis Fistulas.
PubMed 文献 · Kidney Int Rep · 2026-05-08

这项多中心、单盲、随机对照试验纳入170例功能不良且非血栓性动静脉内瘘患者,在成功普通球囊血管成形术后随机加用西罗莫司涂层球囊或安慰剂球囊。结果显示西罗莫司涂层球囊组6个月通路电路初级通畅率显著更高(70.1% vs 56.7%,P=0.03),12个月通畅率在ITT分析中无统计学差异,短期安全性良好。

要点

  • 成功普通球囊扩张后加用西罗莫司涂层球囊可改善6个月通路电路初级通畅率
  • 12个月通畅率在ITT分析中无显著差异,PP分析中仍有差异
  • 短期不良事件少见,30天内两组均无死亡

核心结论

  • 在成功普通球囊血管成形术后使用西罗莫司涂层球囊,可改善功能不良动静脉内瘘患者6个月通路电路初级通畅率,包括存在多处狭窄病变者。
  • 短期安全性结果令人放心。

研究设计与样本

  • 研究者发起的多中心、单盲、随机对照试验(ClinicalTrials.gov标识NCT04409912),在新加坡3家三级教学医院纳入170例患者。
  • 纳入功能不良动静脉内瘘患者,包括通路电路内单发或多发狭窄病变者;在普通球囊血管成形术成功(数字减影血管造影残余狭窄<30%)后随机分组。
  • 采用中心化网络系统随机分配至西罗莫司涂层球囊组(n=83)或安慰剂球囊组(n=87);随访12个月,患者和管理医师对治疗设盲。

主要发现

  • 在意向性治疗(ITT)和符合方案(PP)分析中,西罗莫司涂层球囊组6个月通路电路初级通畅率均显著高于安慰剂组(P=0.03)。
  • 6个月时,西罗莫司涂层球囊组70.1%(95%CI:58.7-78.8)保持通畅,安慰剂组为56.7%(95%CI:45.5-66.4)。
  • 12个月时,ITT分析中通畅率差异无统计学意义(37.1% vs 27.7%;P=0.07),但PP分析中仍有统计学意义(36.4% vs 25.2%;P=0.04)。
  • 两组不良事件均少见,30天内均无死亡。

临床怎么用

  • 对于功能不良的非血栓性动静脉内瘘,在普通球囊血管成形术成功后可考虑加用西罗莫司涂层球囊以改善6个月通畅率。
  • 需注意12个月获益在ITT分析中不显著,临床决策应结合患者具体情况。

局限性

  • 操作者和协调员因球囊外观差异无法设盲。
  • 12个月通畅率在ITT分析中无统计学差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Restenosis following balloon angioplasty remains a major cause of arteriovenous fistula (AVF) dysfunction in patients receiving maintenance hemodialysis. We evaluated whether the use of sirolimus-coated angioplasty balloons (SCBs) improves access circuit primary patency (ACPP) in patients with dysfunctional, nonthrombosed AVFs. METHODS: In this investigator-initiated, multicenter, single-blinded, randomized controlled trial (ClinicalTrials.gov identifier: NCT04409912), we enrolled 170 patients from 3 tertiary teaching hospitals in Singapore. Patients with dysfunctional AVFs, including those with single or multiple stenotic lesions within the access circuit, were included. Following successful plain balloon angioplasty (PBA) (< 30% residual stenosis on digital subtraction angiography), the patients were randomly assigned, using a centralized web-based system, to receive additional treatment with SCB (n = 83) or placebo balloons (n = 87). During the 12-month follow-up, the patients and their managing physicians were blinded to the study treatment and placebo. The proceduralists and coordinators could not be blinded because of visible differences between the balloons. The primary end point was ACPP during the first 6 months after the index procedure. Secondary end points included 12-month patency and safety outcomes. RESULTS: In both intention-to-treat (ITT) and per-protocol (PP) analyses, 6-month ACPP was significantly higher in the SCB group than in the placebo group (P = 0.03). At 6 months, 70.1% (95% confidence interval [CI]: 58.7-78.8) of patients treated with SCB remained patent, compared with 56.7% (95% CI: 45.5-66.4) in the placebo group. At 12 months, the difference in patency was not statistically significant in the ITT analysis (37.1% vs. 27.7%; P = 0.07) but remained significant in the PP analysis (36.4% vs. 25.2%; P = 0.04). Adverse events were infrequent and no deaths occurred within 30 days in both groups. CONCLUSION: Use of SCB following successful PBA improved 6-month ACPP in patients with dysfunctional AVFs, including those with multiple stenotic lesions. Short-term safety findings were reassuring.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tan CS, Tan RY, Ho P, et al. Randomized Controlled Study of Sirolimus-Coated Balloons for Dysfunctional Hemodialysis Fistulas. Kidney Int Rep. 2026. PMID: 42290909. doi:10.1016/j.ekir.2026.106583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。